{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:52Z","timestamp":1781650852566,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum RWTH Aachen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute kidney injury (AKI) is a frequent and clinically relevant complication after cardiac surgery. Early prediction remains challenging because serum creatinine is a delayed and insensitive marker of renal dysfunction. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones with established metabolic functions and emerging roles in cardiovascular, renal, and critical illness\u2013related pathophysiology,\u00a0and their perioperative association with AKI remains incompletely characterised. In this prospective single-centre observational study, 107 adults undergoing elective cardiac surgery were enrolled. Serum GLP-1 and GIP were measured at four time points (preoperatively, immediately postoperatively, and on postoperative days 1 and 4). AKI was defined according to KDIGO criteria. Subgroup analyses excluded patients with chronic kidney disease (CKD). Postoperative AKI occurred in 21 patients (19.6%), predominantly KDIGO stage 1. These patients had longer ICU stays (5 [2\u201312] vs. 3 [1\u201310] days;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), higher SAPS II scores (35 [28\u201339] vs. 29 [25\u201333];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.027), and higher SOFA scores on postoperative days 1 and 4 (both\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Preoperative GLP-1 levels were significantly elevated in patients who developed AKI (38.3 [30\u201352] vs. 27.4 [16.7\u201348.9] pmol\/L;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04), whereas baseline creatinine and GIP did not differ. The association between GLP-1 and AKI remained significant after excluding patients with CKD. Preoperative endogenous GLP-1 levels were associated with postoperative AKI and were elevated earlier in the perioperative course compared with serum creatinine, particularly in patients without CKD. These findings suggest that GLP-1 may reflect early renal stress or vulnerability and warrant further investigation in larger cohorts.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-48483-6","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:35:04Z","timestamp":1777113304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 (GLP-1) levels are associated with acute kidney injury after cardiac surgery"],"prefix":"10.1038","volume":"16","author":[{"given":"Agnieszka","family":"Szafran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkan","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Zechendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kahles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana C","family":"Mossanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"7","key":"48483_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20 (7), 463\u2013474 (2023).","journal-title":"Nat. Rev. Cardiol."},{"issue":"10","key":"48483_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7 (10), 776\u2013785 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"48483_CR3","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee, M. M. Y. et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 48 (5), 846\u2013859 (2025).","journal-title":"Diabetes Care"},{"issue":"10296","key":"48483_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown, E., Heerspink, H. J. L., Cuthbertson, D. J. & Wilding, J. P. H. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398 (10296), 262\u2013276 (2021).","journal-title":"Lancet"},{"issue":"2","key":"48483_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl. J. Med. 391 (2), 109\u2013121 (2024).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"48483_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13 (1), 15\u201328 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"48483_CR7","first-page":"5784","volume":"27","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Effects of water-sodium balance and regulation of electrolytes associated with antidiabetic drugs. Eur. Rev. Med. Pharmacol. Sci. 27 (12), 5784\u20135794 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"48483_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.108.786913","volume":"119","author":"K Karkouti","year":"2009","unstructured":"Karkouti, K. et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 119 (4), 495\u2013502 (2009).","journal-title":"Circulation"},{"issue":"4","key":"48483_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.athoracsur.2011.04.123","volume":"92","author":"G Mariscalco","year":"2011","unstructured":"Mariscalco, G., Lorusso, R., Dominici, C., Renzulli, A. & Sala, A. Acute kidney injury: a relevant complication after cardiac surgery. Ann. Thorac. Surg. 92 (4), 1539\u20131547 (2011).","journal-title":"Ann. Thorac. Surg."},{"issue":"1 Suppl","key":"48483_CR10","first-page":"I409","volume":"114","author":"JR Brown","year":"2006","unstructured":"Brown, J. R. et al. Perioperative increases in serum creatinine are predictive of increased 90-day mortality after coronary artery bypass graft surgery. Circulation 114 (1 Suppl), I409\u2013I413 (2006).","journal-title":"Circulation"},{"issue":"23","key":"48483_CR11","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens, L. A., Coresh, J., Greene, T. & Levey, A. S. Assessing kidney function\u2013measured and estimated glomerular filtration rate. N Engl. J. Med. 354 (23), 2473\u20132483 (2006).","journal-title":"N Engl. J. Med."},{"issue":"2","key":"48483_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/ckj\/sfs008","volume":"5","author":"HR de Geus","year":"2012","unstructured":"de Geus, H. R., Betjes, M. G. & Bakker, J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin. Kidney J. 5 (2), 102\u2013108 (2012).","journal-title":"Clin. Kidney J."},{"key":"48483_CR13","doi-asserted-by":"crossref","unstructured":"Mossanen, J. C. et al. Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery. Int. J. Mol. Sci. 18(8). 1660 (2017).","DOI":"10.3390\/ijms18081662"},{"issue":"4","key":"48483_CR14","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 120 (4), c179\u2013c184 (2012).","journal-title":"Nephron Clin. Pract."},{"issue":"1","key":"48483_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jcmm.12708","volume":"20","author":"D Dreymueller","year":"2016","unstructured":"Dreymueller, D. et al. The perioperative time course and clinical significance of the chemokine CXCL16 in patients undergoing cardiac surgery. J. Cell. Mol. Med. 20 (1), 104\u2013115 (2016).","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"48483_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12902-024-01566-9","volume":"24","author":"DB Zilstorff","year":"2024","unstructured":"Zilstorff, D. B. et al. Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males. BMC Endocr. Disord. 24 (1), 38 (2024).","journal-title":"BMC Endocr. Disord"},{"key":"48483_CR17","doi-asserted-by":"crossref","unstructured":"Wang, A. et al. Perioperative considerations of novel antidiabetic agents in heart failure patients undergoing cardiac surgery. Life (Basel) 15(3). 397 (2025).","DOI":"10.3390\/life15030427"},{"issue":"7","key":"48483_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.amjmed.2017.03.010","volume":"130","author":"C Lebherz","year":"2017","unstructured":"Lebherz, C. et al. GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease. Am. J. Med. 130 (7), 833\u201341e3 (2017).","journal-title":"Am. J. Med."},{"issue":"7","key":"48483_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/eurheartj\/ehz728","volume":"41","author":"F Kahles","year":"2020","unstructured":"Kahles, F. et al. Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. Eur. Heart J. 41 (7), 882\u2013889 (2020).","journal-title":"Eur. Heart J."},{"issue":"1","key":"48483_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2215\/CJN.0000000000000566","volume":"20","author":"A Ahmadi","year":"2025","unstructured":"Ahmadi, A. et al. Impaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD. Clin. J. Am. Soc. Nephrol. 20 (1), 12\u201322 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"48483_CR21","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","volume":"84","author":"I Caruso","year":"2024","unstructured":"Caruso, I. & Giorgino, F. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Endocrine 84 (3), 822\u2013835 (2024).","journal-title":"Endocrine"},{"key":"48483_CR22","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera, F. B. et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am. J. Prev. Cardiol. 18, 100679 (2024).","journal-title":"Am. J. Prev. Cardiol."},{"issue":"6","key":"48483_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.34067\/KID.0000000000000466","volume":"5","author":"FG Scurt","year":"2024","unstructured":"Scurt, F. G., Bose, K., Mertens, P. R., Chatzikyrkou, C. & Herzog, C. Cardiac Surgery-Associated Acute Kidney Injury. Kidney360 5 (6), 909\u2013926 (2024).","journal-title":"Kidney360"},{"key":"48483_CR24","doi-asserted-by":"crossref","unstructured":"Drucker, D. J. The GLP-1 journey: from discovery science to therapeutic impact. J. Clin. Invest. 134(2), e175413 (2024).","DOI":"10.1172\/JCI175634"},{"issue":"10","key":"48483_CR25","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2337\/db14-0100","volume":"63","author":"F Kahles","year":"2014","unstructured":"Kahles, F. et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63 (10), 3221\u20133229 (2014).","journal-title":"Diabetes"},{"issue":"2","key":"48483_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2337\/db13-0903","volume":"63","author":"AT Nguyen","year":"2014","unstructured":"Nguyen, A. T. et al. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 63 (2), 471\u2013482 (2014).","journal-title":"Diabetes"},{"issue":"5","key":"48483_CR27","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.celrep.2017.10.008","volume":"21","author":"LJ Lebrun","year":"2017","unstructured":"Lebrun, L. J. et al. Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. Cell. Rep. 21 (5), 1160\u20131168 (2017).","journal-title":"Cell. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48483-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48483-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:44:10Z","timestamp":1781649850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48483-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48483-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.K. has served as a speaker for SphingoTec\/4TEEN4 Pharmaceuticals and Novo Nordisk and received travel reimbursement from 4TEEN4 Pharmaceuticals, Novo Nordisk, the German Society of Lipidology, the German Cardiac Society, Boehringer Ingelheim, and Lilly.\u00a0F.K. has served as a speaker for Novo Nordisk, Amgen, Lilly, AstraZeneca, C.T.I., Cogitando, and DGK-Akademie; consulted for Novo Nordisk, Lilly, Bayer, and PricewaterhouseCoopers\/Strategy&; and received travel support from Amgen, Novo Nordisk, Boehringer Ingelheim, Bayer, SphingoTec\/4TEEN4 Pharmaceuticals, C.T.I., Cogitando, and Lilly.\u00a0All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13408"}}